Fig 1.


(A) Progression-free survival by treatment.
FND→R, sequential fludarabine, mitoxantrone, dexamethasone followed by rituximab; RFND, concurrent fludarabine, mitoxantrone, dexamethasone and rituximab.
(B) Progression-free survival by Follicular Lymphoma International Prognostic Index (FLIPI) score